AU2020227748A1 - Method for treating a multiple myeloma - Google Patents

Method for treating a multiple myeloma Download PDF

Info

Publication number
AU2020227748A1
AU2020227748A1 AU2020227748A AU2020227748A AU2020227748A1 AU 2020227748 A1 AU2020227748 A1 AU 2020227748A1 AU 2020227748 A AU2020227748 A AU 2020227748A AU 2020227748 A AU2020227748 A AU 2020227748A AU 2020227748 A1 AU2020227748 A1 AU 2020227748A1
Authority
AU
Australia
Prior art keywords
compound
subject
multiple myeloma
pharmaceutical composition
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020227748A
Other languages
English (en)
Inventor
Arnold BOLOMSKY
Liangxian Cao
Heinz Ludwig
Marla L. Weetall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of AU2020227748A1 publication Critical patent/AU2020227748A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020227748A 2019-02-28 2020-02-26 Method for treating a multiple myeloma Abandoned AU2020227748A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812002P 2019-02-28 2019-02-28
US62/812,002 2019-02-28
PCT/US2020/019884 WO2020176610A1 (en) 2019-02-28 2020-02-26 Method for treating a multiple myeloma

Publications (1)

Publication Number Publication Date
AU2020227748A1 true AU2020227748A1 (en) 2021-09-16

Family

ID=72238680

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020227748A Abandoned AU2020227748A1 (en) 2019-02-28 2020-02-26 Method for treating a multiple myeloma

Country Status (11)

Country Link
US (1) US20220143016A1 (enExample)
EP (1) EP3931196A4 (enExample)
JP (1) JP2022521801A (enExample)
CN (1) CN113710670A (enExample)
AU (1) AU2020227748A1 (enExample)
BR (1) BR112021016747A2 (enExample)
CA (1) CA3131249A1 (enExample)
EA (1) EA202192117A1 (enExample)
IL (1) IL285800A (enExample)
MX (1) MX2021010398A (enExample)
WO (1) WO2020176610A1 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
EP2624818B1 (en) * 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Bortezomib formulations stabilised with boric acid
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
MX370588B (es) * 2013-08-30 2019-12-16 Ptc Therapeutics Inc Inhibidores de la bmi-1 de pirimidina sustituida.
JP2021535198A (ja) * 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Also Published As

Publication number Publication date
US20220143016A1 (en) 2022-05-12
WO2020176610A1 (en) 2020-09-03
EP3931196A4 (en) 2022-12-14
MX2021010398A (es) 2022-01-18
CN113710670A (zh) 2021-11-26
EA202192117A1 (ru) 2021-11-23
CA3131249A1 (en) 2020-09-03
EP3931196A1 (en) 2022-01-05
JP2022521801A (ja) 2022-04-12
WO2020176610A8 (en) 2021-08-12
IL285800A (en) 2021-10-31
BR112021016747A2 (pt) 2021-10-19

Similar Documents

Publication Publication Date Title
US11458126B2 (en) DHODH inhibitor for use in treating hematologic cancers
US20210353596A1 (en) Combination treatment of cancer
KR20170078811A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법
JP2025032069A (ja) 膵臓癌を治療する方法
US20220143016A1 (en) Method for treating a multiple myeloma
AU2020209767B2 (en) Method for treating an acute myeloid leukemia
RU2812782C2 (ru) Способ лечения острого миелоидного лейкоза
US20220152024A1 (en) Combinations useful in a method for treating sarcoma
EA047152B1 (ru) Способ лечения множественной миеломы
EA046841B1 (ru) Комбинации, пригодные в способе лечения саркомы

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted